PUBLICATIONS, NEWS & EVENTS
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Round led by new investor Panakes, with participation from…
January 30, 2024/by adminEnterprise Therapeutics appoints Dr Niyati Prasad as Chief Medical Officer
Dr Prasad will lead Enterprise’s development strategy to support…
February 8, 2022/by adminEnterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
ETD001 is a novel inhaled, long-acting ENaC inhibitor
Therapy…
June 14, 2021/by adminTherapy…
Enterprise Therapeutics’ First-in-Class TMEM16A potentiator program for treatment of cystic fibrosis and other respiratory diseases acquired by Roche
Enterprise’s novel TMEM16A potentiator portfolio includes…
October 7, 2020/by adminEnterprise Therapeutics doses first subjects in Phase 1 trial for First-in-Class cystic fibrosis therapy ETD002
ETD002 is a novel TMEM16A chloride channel potentiator
…
August 17, 2020/by admin…
Enterprise Therapeutics appoints Dr David Morris MD as Chief Medical Officer
Dr Morris will lead Enterprise’s therapeutics development strategy…
February 10, 2020/by adminEnterprise Therapeutics publishes paper on novel therapeutic approach for treatment of all cystic fibrosis patients
“TMEM16A Potentiation: A Novel Therapeutic Approach for…
January 8, 2020/by adminTMEM16A Channel Function Does Not Influence Goblet Cell Numbers or Mucin Secretion In The Human Airway Epithelium – NACFC – Nashville – October 2019
TMEM16A Channel Function Does Not Influence Goblet Cell Numbers…
November 7, 2019/by adminEACT Increases Intracellular Calcium Levels by a Tmem16a-Independent Mechanism – NACFC – Nashville – October 2019
EACT Increases Intracellular Calcium Levels by a Tmem16a-Independent…
November 7, 2019/by adminThe In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator Compounds – NACFC – Nashville – October 2019
The In Vitro & In Vivo Pharmacology of Novel Tmem16a Potentiator…
November 7, 2019/by adminEnterprise Therapeutics awarded up to £5.7M ($7M) from Cystic Fibrosis Foundation to Support Clinical Development of Novel Chloride Channel Modulator
Support for clinical development up to end of Phase 2 for…
October 15, 2019/by adminECFS Clinical Meeting Liverpool TMEM16A potentiator
ECFS Clinical Meeting Liverpool TMEM16A potentiator
Objectives:…
October 9, 2019/by adminObjectives:…
